- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06051760
NV-001 in the Treatment of Advanced Solid Tumors
A Phase I Study to Explore the Safety and Efficacy of NV-001 in the Treatment of Advanced Solid Tumors
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Dr. Wang
- Phone Number: 86(010)87788495
- Email: snowflake201@gmail.com
Study Locations
-
-
-
Beijing, China
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients with histopathologically and/or cytologically confirmed non-surgically resectable advanced/metastatic solid tumors.
- patients with progression on prior standard treatment regimens or intolerance to standard treatment or no standard treatment.
- an Eastern Cooperative Oncology Group (ECOG) Physical Status (PS) score of 0 or 1 and an expected survival time of ≥12 weeks
- confirmed clinical or imaging progression after the most recent antitumor therapy: at least 1 measurable lesion according to RECIST 1.1 criteria.
- Substantially normal major organ function and screening laboratory values that meet the following criteria:
A. Bone marrow function: absolute neutrophil count ≥ 1000/μL; hemoglobin ≥ 9g/dL; platelet count ≥ 75,000/μL.
B. Liver function: serum total bilirubin ≤ 1.5 x upper limit of normal (ULN); serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 x ULN (patients with liver metastases should be ≤ 5 x ULN); alkaline phosphatase < 2.5 x ULN (patients with liver and bone involvement should be ≤ 5 x ULN).
C. Renal Function: Serum creatinine ≤ 2.5 x ULN, or creatinine clearance ≥ 30 mL/min, whether actually measured by urine collection or estimated using the Cockcroft-Gault formula.
D. coagulation: prothrombin time (PT), International Normalized Ratio (INR), and Partial Thromboplastin Time (PTT) ≤ 1.5 × ULN.
- presence of biopsy lesions with acceptable clinical risk or lesions amenable to palliative surgical resection. Presence of a tumor lesion amenable to tumor tissue biopsy.
- have an expected survival of more than 12 weeks.
- the patient understands and complies with the study protocol and has signed the appropriate Informed Consent Form (ICF), which must be signed prior to the study procedure. 11. for patients of childbearing potential, the patient must be able to understand and comply with the study protocol.
- For patients of childbearing potential: Patients should agree to use effective contraception during treatment and for at least 90 days after the last dose of study treatment, including double-barrier contraception, condoms, contraceptive pills or injectables, and intrauterine devices (IUDs). Male patients should agree to avoid sperm donation.
Exclusion Criteria:
- has received other systemic antitumor therapy within 28 days or 5 half-lives prior to the first treatment. or has not recovered from the previous treatment (all three cases, whichever is longer);
- has received radiotherapy within 14 days prior to the first dose.
- has received a live or live attenuated vaccine within 30 days prior to the first dose.
- use of immunosuppressive drugs currently or within 14 days prior to the first dose.
- has had major surgery within 28 days or non-study related minor surgery within 7 days prior to the first dose.
- the patient has a history of allergic or hypersensitivity reactions to any of the components of NV-001.
- female patients who are breastfeeding or have a positive serum pregnancy test at the time of the screening visit.
- insufficient biopsy to complete the experiment
- any Grade 4 immune-related AE (irAE) on prior immunotherapy (patients with endocrine disorders receiving replacement therapy or experiencing asymptomatic elevations in serum amylase or lipase are eligible for enrollment), any irAE on prior immunotherapy that resulted in permanent discontinuation of therapy, or any Grade 3 irAE within ≤ 6 months prior to initiation of treatment.
- prior toxicity from antineoplastic therapy that remains at NCI-CTCAE ≥ Grade 2 (except for alopecia, vitiligo, and experimental indications of Grade 2 or higher as defined in the Inclusion Criteria); subjects with neurotoxicity ≥ Grade 2 may be eligible for enrollment at the discretion of the Investigator; subjects with irreversible toxicity may be eligible for enrollment at the discretion of the Investigator.
- the presence of clinically significant pulmonary fibrosis or interstitial pneumonitis as determined by the investigator.
- the presence of clinically significant severe ophthalmic disease as determined by the investigator based on screening ophthalmologic examination.
- the presence of other malignant tumors within the previous 5 years, with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.
prolonged use (≥14 consecutive days) of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids: prednisone or equivalent) within 6 months, except that topical medications (e.g., ointments, eye drops, inhalers, or nasal sprays) are permitted, and topical medications must not exceed the dose recommended in the insert or if there are any signs of systemic exposure; or other acquired or congenital immunodeficiency diseases; or History of organ transplantation.
- the presence of clinically symptomatic central nervous system tumors or metastases.
- the presence of an active infection including tuberculosis (documented history, investigator judgment and radiology, and local laboratory testing), hepatitis B (hepatitis B surface antigen positive, HBV DNA above the lower limit of detection), hepatitis C (HCV antibody positive, HCV RNA positive), HIV (HIV antibody positive), and enrolled patients with viral load-negative HBV or HCV who have consented to Antiviral therapy and/or regular viral indicator monitoring as determined by the physician.
- documented primary immunodeficiency or organ transplantation.
- subjects with a history of active gastrointestinal bleeding, hemoptysis or hemorrhage.
- other conditions that may result in increased risk associated with the study medication, or affect compliance with the trial, which in the opinion of the investigator make participation in this trial inappropriate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NV-001
The patients will be treated with vaccines generated based on their tumor tissues.Various doses will be tested according to the protocol.
|
NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing Adverse Events (AEs)
Time Frame: From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
Number of Participants Experiencing Adverse Events (AEs)
|
From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Time Frame: in the first 28 days after the first dose.
|
Number of Participants Experiencing dose-limiting toxicities (DLTs)
|
in the first 28 days after the first dose.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 36 month
|
Overall Response Rate (ORR)
|
Up to 36 month
|
Disease Control Rate(DCR)
Time Frame: Up to 36 month
|
Disease Control Rate(DCR)
|
Up to 36 month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Up to 36 month
|
Progression-Free Survival (PFS)
|
Up to 36 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NV-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasm
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
Clinical Trials on NV-001
-
Navitor Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.RecruitingMajor Depressive DisorderUnited States
-
Intermountain Health Care, Inc.NuView DiagnosticsUnknownProstate Cancer | Kidney Stones | Benign Prostatic Hypertrophy | Bladder StonesUnited States
-
First Affiliated Hospital of Wannan Medical CollegeRecruiting
-
Navitor Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.RecruitingTreatment Resistant DepressionUnited States
-
Supernus Pharmaceuticals, Inc.Completed
-
Ramsay Générale de SantéEuropean Clinical Trial Experts NetworkNot yet recruitingChronic Renal Failure | Heparin-induced Thrombocytopenia | Dialysis; ComplicationsFrance
-
Navitor Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.Completed
-
Navitor Pharmaceuticals, Inc.CompletedTreatment Resistant DepressionUnited States
-
Qassim UniversityRecruiting
-
Universitair Ziekenhuis BrusselCompleted